C-FKWTLongeveron Inc
cell therapy, regenerative medicine, stem cells
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FKWT
C-FKWTC-FKWTcell therapy, regenerative medicine, stem cells
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Longeveron states that it is developing biological solutions for aging and aging-associated diseases and believes regenerative medicine through cell-based therapy is a promising new approach for treating conditions such as Aging Frailty, Alzheimer’s disease, and Metabolic Syndrome, all of which it describes as having limited therapies and no cure.
SourceLongeveron states that it is developing biological solutions for aging and aging-associated diseases, and that regenerative medicine through cell-based therapy is a promising new way to treat these conditions. The company presents its stem-cell therapy program as a potential treatment approach for Aging Frailty, Alzheimer's disease, and Metabolic Syndrome, all of which it describes as serious conditions with limited therapies and no cure to date.
SourceLongeveron states that extending healthy life expectancy is increasingly important as people live longer, and that aging-related frailty is a major clinical and societal problem that reduces quality of life, increases vulnerability and mortality, and raises healthcare costs. The company presents its position that a biological, cell-based therapeutic approach can address frailty and other age-related conditions and help transform aging by improving health and quality of life in later years.
SourceLongeveron states that as human lifespans increase, society must focus on improving healthy life expectancy and quality of life in old age. It presents frailty as a major age-related syndrome driving decline, loss of independence, mortality, and healthcare burden, and says it believes safe cell-based biological therapies can address frailty and other aging-related conditions and help transform the aging process.
SourceLongeveron states that it is developing biological solutions for aging and aging-associated diseases and believes regenerative medicine, specifically cell-based therapy, is a promising new approach for treating these conditions. The company presents its stem-cell-based product as being evaluated in FDA clinical trials for Aging Frailty and also being tested for Alzheimer’s disease and Metabolic Syndrome, emphasizing that these are serious conditions with limited therapies and no cure.
Source